| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 502,1 k € | — | 466,9 k € | — | |||||||||||||||||||
| Gross margin | 237,9 k € | +11.7% | 213,0 k € | -41.1% | 361,8 k € | -27.7% | 500,4 k € | +8.2% | 462,3 k € | +1891.6% | -25,8 k € | -114.0% | 184,9 k € | +124.7% | 82,3 k € | -58.3% | 197,3 k € | -20.5% | 248,0 k € | -16.8% | 298,0 k € | +44.1% | 206,7 k € | +3.2% | 200,3 k € | +27.5% | 157,1 k € | +13.1% | 138,8 k € | +16.3% | 119,4 k € | -13.5% | 138,1 k € | +14.5% | 120,6 k € | +50.6% | 80,1 k € | |
| EBITDA | 232,4 k € | +10.9% | 209,6 k € | -41.5% | 358,2 k € | -27.9% | 496,8 k € | +8.4% | 458,4 k € | +1644.3% | -29,7 k € | -116.4% | 180,8 k € | +131.5% | 78,1 k € | -59.7% | 193,8 k € | -20.7% | 244,2 k € | -16.9% | 294,0 k € | +44.7% | 203,1 k € | +3.2% | 196,8 k € | +27.1% | 154,8 k € | +12.2% | 137,9 k € | +16.9% | 118,0 k € | -13.9% | 137,1 k € | +19.4% | 114,8 k € | +46.1% | 78,6 k € | |
| Operating profit | 186,0 k € | +19.7% | 155,4 k € | -48.9% | 303,9 k € | -31.2% | 441,8 k € | +7.6% | 410,7 k € | +694.6% | -69,1 k € | -146.2% | 149,4 k € | +284.9% | 38,8 k € | -74.9% | 154,4 k € | -25.0% | 206,0 k € | -19.3% | 255,4 k € | +49.1% | 171,2 k € | -3.3% | 177,2 k € | +44.0% | 123,0 k € | +13.1% | 108,8 k € | +23.8% | 87,9 k € | -19.6% | 109,3 k € | +26.0% | 86,7 k € | +58.4% | 54,7 k € | |
| Profit/loss | 160,7 k € | +63.9% | 98,1 k € | -50.4% | 197,5 k € | -40.1% | 329,9 k € | +12.8% | 292,5 k € | +518.5% | -69,9 k € | -185.1% | 82,1 k € | +297.3% | 20,7 k € | -77.1% | 90,2 k € | -25.8% | 121,5 k € | -20.5% | 152,7 k € | -5.9% | 162,3 k € | +45.7% | 111,4 k € | +53.2% | 72,7 k € | -8.2% | 79,2 k € | +18.8% | 66,7 k € | -17.8% | 81,1 k € | +6.7% | 76,1 k € | +82.4% | 41,7 k € | |
| Equity | 1,2 M € | +15.1% | 1,1 M € | +10.2% | 963,2 k € | -14.8% | 1,1 M € | +41.2% | 801,1 k € | +57.5% | 508,6 k € | -12.1% | 578,5 k € | -19.8% | 721,4 k € | +2.9% | 700,7 k € | +14.8% | 610,6 k € | +24.8% | 489,1 k € | +339.2% | 111,4 k € | -67.8% | 346,0 k € | +3.8% | 333,2 k € | -7.6% | 360,5 k € | +2.6% | 351,2 k € | -8.8% | 384,9 k € | +26.7% | 303,8 k € | +33.4% | 227,7 k € | |
| Total assets | 1,6 M € | +10.2% | 1,4 M € | -3.1% | 1,5 M € | -5.1% | 1,5 M € | +12.9% | 1,4 M € | +18.0% | 1,1 M € | +10.5% | 1,0 M € | +0.7% | 1,0 M € | -7.2% | 1,1 M € | +4.0% | 1,1 M € | -4.2% | 1,1 M € | -1.4% | 1,1 M € | +11.2% | 1,0 M € | +33.0% | 765,2 k € | +1.2% | 755,9 k € | +47.2% | 513,5 k € | +12.9% | 455,0 k € | +19.0% | 382,3 k € | +41.8% | 269,6 k € | |
| Cash | 57,4 k € | -58.6% | 138,7 k € | -52.9% | 294,4 k € | -21.6% | 375,3 k € | +33.1% | 282,0 k € | +92.8% | 146,3 k € | +69.4% | 86,3 k € | +118.9% | 39,4 k € | -40.4% | 66,1 k € | -32.7% | 98,3 k € | -9.1% | 108,1 k € | +19.4% | 90,5 k € | -37.1% | 143,9 k € | +63.1% | 88,2 k € | -71.3% | 307,9 k € | -8.0% | 334,5 k € | +168.3% | 124,7 k € | +71.2% | 72,8 k € | -34.8% | 111,7 k € | |
| Debts | 251,3 k € | -10.0% | 279,1 k € | -35.4% | 432,1 k € | +25.6% | 343,9 k € | -33.0% | 513,5 k € | -18.8% | 632,3 k € | +39.9% | 451,9 k € | +45.5% | 310,5 k € | -24.5% | 411,1 k € | -10.4% | 458,6 k € | -26.5% | 624,1 k € | -38.7% | 1,0 M € | +53.0% | 665,1 k € | +54.2% | 431,3 k € | +9.4% | 394,1 k € | +144.1% | 161,5 k € | +130.4% | 70,1 k € | -7.0% | 75,3 k € | +80.0% | 41,9 k € | |
Private limited company · Oosterzele · incorporated on 12/12/2001
Private limited company profitable and well capitalised. Cash position declining (-58.6%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
DR. STEFAN DE MAESENEIRE is a Private limited company incorporated in 2001. Its main activity is: Other human health activities. Its registered office is in Oosterzele.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette